During the past seven years, CFTR modulators including Kalydeco® (2012), Orkambi® (2015), Symdeko® (2018) and Trikafta® (2019) have been clinically used to correct the root causes of CF. The gene discussed is CFTR; the disease is cystic fibrosis.